InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Positive Phase 1 Results for TNX-1500 in Transplant and Autoimmune Therapy
Tonix Pharmaceuticals (NASDAQ: TNXP) announced positive topline results from its Phase 1 trial of TNX-1500, an Fc-modified humanized anti-CD40L monoclonal antibody, in healthy participants. The study demonstrated TNX-1500 was well tolerated, with no serious adverse events or thromboembolic complications, and effectively blocked immune responses at higher doses. The pharmacokinetics support monthly dosing at 10 mg/kg or above, positioning the drug as a potential best-in-class therapy…